We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
Cap. Flow
-$160M
Cap. Flow %
-10.45%
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$13.5M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$11.9M
3
ESPR
Esperion Therapeutics
ESPR
+$4.02M
4
AIXC
AIxCrypto Holdings Inc
AIXC
+$2.59M
5
HURA
TuHURA Biosciences
HURA
+$2.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$59.2M
2
UTHR icon
United Therapeutics
UTHR
+$6.78M
3
TSRO
TESARO, Inc.
TSRO
+$5.95M
4
KITE
Kite Pharma, Inc.
KITE
+$4.37M
5
SPNC
Spectranetics Corp
SPNC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 7.34%
2 Technology 0.16%
3 Materials 0.11%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBVT
26
PUT
DBV Technologies
DBVT
$824M
$7.57M 0.49%
+178
New +$76.3K
KYNB
27
CALL
Kyntra Bio
KYNB
$28.2M
$7.45M 0.49%
55
-6
-10% -$6.32K
ESPR
28
PUT
DELISTED
Esperion Therapeutics
ESPR
$7.41M 0.48%
1,479
+1,222
+475% +$58.9K
IONS icon
29
CALL
Ionis Pharmaceuticals
IONS
$8.9B
$7.21M 0.47%
1,423
+130
+10% +$6.81K
AZN icon
30
PUT
AstraZeneca
AZN
$270B
$6.92M 0.45%
1,022
-891
-47% -$56.3K
PRTA icon
31
CALL
Prothena Corp
PRTA
$451M
$6.47M 0.42%
999
+146
+17% +$8.94K
UTHR icon
32
CALL
United Therapeutics
UTHR
$26.1B
$6.35M 0.42%
542
-821
-60% -$105K
FOLD
33
CALL
DELISTED
Amicus Therapeutics
FOLD
$6.24M 0.41%
4,138
-820
-17% -$10.8K
SGMO
34
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.98M 0.39%
3,984
+92
+2% +$1.02K
INSM icon
35
PUT
Insmed
INSM
$22.9B
$5.78M 0.38%
1,851
-48
-3% -$914
AMAG
36
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$5.54M 0.36%
3,004
+864
+40% +$16.1K
SIOX
37
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.28M 0.35%
960
+494
+106% +$83.3K
CYTK icon
38
CALL
Cytokinetics
CYTK
$10.8B
$4.93M 0.32%
3,398
+256
+8% +$3.5K
ZGNX
39
PUT
DELISTED
Zogenix, Inc.
ZGNX
$4.47M 0.29%
1,275
-2,550
-67% -$34.6K
INCY icon
40
CALL
Incyte
INCY
$25.8B
$4.46M 0.29%
382
+100
+35% +$12.7K
AMRN
41
CALL
Amarin Corp
AMRN
$298M
$4.43M 0.29%
633
-75
-11% -$5.31K
SIOX
42
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$4.42M 0.29%
+80,320
New +$13.5M
SAGE
43
CALL
DELISTED
Sage Therapeutics
SAGE
$4.37M 0.29%
702
+278
+66% +$21.8K
INSM icon
44
CALL
Insmed
INSM
$22.9B
$4.29M 0.28%
1,375
+674
+96% +$12.8K
ESPR
45
DELISTED
Esperion Therapeutics
ESPR
$4.18M 0.27%
+83,357
New +$4.02M
GILD icon
46
CALL
Gilead Sciences
GILD
$166B
$3.68M 0.24%
454
– –
OTLK icon
47
Outlook Therapeutics
OTLK
$184M
$3.27M 0.21%
14,900
+114
+0.8% +$20.7K
FPRX
48
PUT
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.1M 0.2%
+758
New +$23.8K
SGEN
49
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$2.95M 0.19%
542
+104
+24% +$5.33K
GWPH
50
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.89M 0.19%
28,517
+12,803
+81% +$1.37M
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.

Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.

  • Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
  • Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
  • Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
  • Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
  • Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
  • Sabby Management opened 32 new positions and closed 82 in Q3 2017.
  • Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.